Clinical Trial Update: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating futibatinib in combination with a PD-1 antibody-based standard of care for locally advanced unresectable or metastatic solid tumors, in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastroesophageal Junction Cancer
• Pancreatic Cancer

Drugs mentioned

• Futibatinib (TAS-120) (futibatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING